BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29937236)

  • 1. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
    Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N
    Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
    Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
    Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.
    Kerr M; Pears R; Miedzybrodzka Z; Haralambos K; Cather M; Watson M; Humphries SE
    Eur Heart J; 2017 Jun; 38(23):1832-1839. PubMed ID: 28387827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
    Hendy LE; Spees LP; Tak C; Carpenter DM; Thomas KC; Roberts MC
    Atherosclerosis; 2024 Jun; 393():117541. PubMed ID: 38677159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
    Chen CX; Hay JW
    Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.
    Qureshi N; Woods B; Neves de Faria R; Saramago Goncalves P; Cox E; Leonardi Bee J; Condon L; Weng S; Akyea RK; Iyen B; Roderick P; Humphries SE; Rowlands W; Watson M; Haralambos K; Kenny R; Datta D; Miedzybrodzka Z; Byrne C; Kai J
    Health Technol Assess; 2023 Oct; 27(16):1-140. PubMed ID: 37924278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
    Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
    J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation.
    Ankcorn MJ; Tedder RS; Cairns J; Sandmann FG
    Value Health; 2020 Mar; 23(3):309-318. PubMed ID: 32197726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
    König HH; Barry JC
    Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
    Truong TH; Kim NT; Nguyen MNT; Pang J; Hooper AJ; Watts GF; Do DL
    Atherosclerosis; 2018 Oct; 277():392-398. PubMed ID: 30270076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic evaluation of an abdominal aortic aneurysm screening program in Italy.
    Giardina S; Pane B; Spinella G; Cafueri G; Corbo M; Brasseur P; Orengo G; Palombo D
    J Vasc Surg; 2011 Oct; 54(4):938-46. PubMed ID: 21820837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
    Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
    J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
    Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
    Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.